Patent search ap:("Pfizer Inc.") AND inv:"Ravi G. Kurumbail" Page 1

1.

发明申请
RORC2 INHIBITORS AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：US20170233371A1

公开(公告)日：2017-08-17

申请号：US15497862

申请日：2017-04-26

Applicant: Pfizer Inc.

Inventor： Mark Edward Schnute , Gõran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, Jr. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones

IPC: C07D401/14 , C07D413/14 , C07D405/14 , C07D413/04 , C07D471/04 , C07D487/04 , C07D403/04 , C07D401/04 , C07D417/14

CPC classification number: C07D401/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D403/04 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , Y02A50/406 , A61K2300/00

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

2.

发明申请
RORC2 INHIBITORS AND METHODS OF USE THEREOF 审中-公开
Title translation: RORC2抑制剂及其使用方法

公开(公告)号：US20160046597A1

公开(公告)日：2016-02-18

申请号：US14448220

申请日：2014-07-31

Applicant: PFIZER INC.

Inventor： Mark Edward Schnute , Göran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, JR. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones

IPC: C07D401/04 , C07D413/14 , C07D403/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D401/14 , C07D405/14

CPC classification number: C07D401/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D403/04 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , Y02A50/406 , A61K2300/00

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract translation: 本发明提供化合物，药物组合物，抑制受试者的RORγ活性和/或减少IL-17的量的方法，以及使用这些化合物和药物组合物治疗各种医学病症的方法。

3.

发明申请
Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors 审中-公开
Title translation: 新的咪唑并[4,5-c]喹啉和咪唑并[4,5-c] [1,5]萘啶衍生物作为LRRK2抑制剂

公开(公告)号：US20170073343A1

公开(公告)日：2017-03-16

申请号：US15262112

申请日：2016-09-12

Applicant: Pfizer Inc.

Inventor： Paul Galatsis , Jaclyn Louise Henderson , Bethany Lyn Kormos , Ravi G. Kurumbail , Matthew Richard Reese , Antonia Friederike Stepan , Patrick Robert Verhoest , Travis T. Wager , Martin Youngjin Pettersson , Michelle Renee Garnsey

IPC: C07D471/04 , C07D471/14 , C07D519/00

CPC classification number: A61K31/435 , A61K31/4745 , C07D215/38 , C07D215/42 , C07D471/04 , C07D471/14 , C07D519/00

Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Abstract translation: 其中R1，R1a，R1b，R2，R4，R5，R6，X和Z如说明书中所定义。本发明还涉及包含式（I）化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默氏病，癌症，克罗恩病或麻风病的神经变性疾病。

4.

发明申请
Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors 审中-公开
Title translation: 新型4-（取代氨基）-7H-吡咯并[2,3-d]嘧啶作为LRRK2抑制剂

公开(公告)号：US20140005183A1

公开(公告)日：2014-01-02

申请号：US13928696

申请日：2013-06-27

Applicant: Pfizer Inc.

Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Antonia Friederike Stepan , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest

IPC: C07D487/04 , C07D519/00

CPC classification number: A61K31/5377 , C07D487/04 , C07D519/00

Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Abstract translation: 本发明提供了式I的新的4,5-二取代的-7H-吡咯并[2,3-d]嘧啶衍生物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如说明书中所定义。本发明还涉及包含式I化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默病，神经变性疾病或克罗恩病或麻风病的神经变性疾病。

5.

发明授权
Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors 有权

公开(公告)号：US09642855B2

公开(公告)日：2017-05-09

申请号：US14840528

申请日：2015-08-31

Applicant: Pfizer Inc.

Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Antonia Friederike Stepan , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest

IPC: A61K31/519 , C07D487/04 , A61K31/5377 , C07D519/00

CPC classification number: A61K31/5377 , C07D487/04 , C07D519/00

Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

6.

发明申请
NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS 审中-公开
Title translation: 新的3,4-取代的1H-吡咯并[2,3-b]吡啶和4,5-取代的-7H-吡咯并[2,3-c]吡咯烷作为LRRK2抑制剂

公开(公告)号：US20170002000A1

公开(公告)日：2017-01-05

申请号：US15104659

申请日：2014-12-03

Applicant: PFIZER INC.

Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest , Antonia Friederike Stepan

IPC: C07D471/04 , C07D491/08 , C07D498/08 , C07D519/00 , C07D487/04

CPC classification number: C07D471/04 , C07D487/04 , C07D491/08 , C07D498/08 , C07D519/00

Abstract: The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Abstract translation: 其中R1，R2，R3，R4和X如说明书中所定义。本发明还涉及包含式I化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默病，神经变性疾病或克罗恩病或麻风病的神经变性疾病。

7.

发明授权
4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors 有权
Title translation: 4-（取代氨基）-7H-吡咯并[2,3-d]嘧啶作为LRRK2抑制剂

公开(公告)号：US09156845B2

公开(公告)日：2015-10-13

申请号：US13928696

申请日：2013-06-27

Applicant: Pfizer Inc.

Inventor： Paul Galatsis , Matthew Merrill Hayward , Bethany Lyn Kormos , Travis T. Wager , Lei Zhang , Antonia Friederike Stepan , Jaclyn Louise Henderson , Ravi G. Kurumbail , Patrick Robert Verhoest

IPC: A61K31/519 , C07D207/18 , C07D487/04 , C07D519/00

CPC classification number: A61K31/5377 , C07D487/04 , C07D519/00

Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Abstract translation: 本发明提供了式I的新的4,5-二取代的-7H-吡咯并[2,3-d]嘧啶衍生物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如说明书中所定义。本发明还涉及包含式I化合物的药物组合物，以及该化合物在治疗与LRRK2相关的疾病中的应用，例如包括帕金森病或阿尔茨海默病，神经变性疾病或克罗恩病或麻风病的神经变性疾病。